Tradename | Company | Number | Date | Products |
---|---|---|---|---|
NITYR | Cycle Pharmaceuticals | N-209449 RX | 2017-07-26 | 3 products, RLD, RS |
ORFADIN | Orphan Medical | N-021232 RX | 2002-01-18 | 4 products, RLD |
ORFADIN | Orphan Medical | N-206356 RX | 2016-04-22 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
nitisinone | ANDA | 2024-12-12 |
nityr | New Drug Application | 2024-05-24 |
orfadin | New Drug Application | 2022-06-20 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
tyrosinemias | — | D020176 | E70.21 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Tyrosinemias | D020176 | — | E70.21 | 3 | — | — | — | — | 3 |
Drug common name | Nitisinone |
INN | nitisinone |
Description | Nitisinone is a cyclohexanone that is cyclohexane-1,3-dione substituted at position 2 by a 2-nitro-4-(trifluoromethyl)benzoyl group. It is used in the treatment of hereditary tyrosinemia type 1. It has a role as an EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor. It is a member of cyclohexanones, a C-nitro compound, a member of (trifluoromethyl)benzenes and a mesotrione. ... More |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-] |
PDB | — |
CAS-ID | 104206-65-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1337 |
ChEBI ID | 50378 |
PubChem CID | 115355 |
DrugBank | DB00348 |
UNII ID | K5BN214699 (ChemIDplus, GSRS) |